Paramyxoviridae Infections [clinicaltrials_resource:aeef3dc206d9c8dcfa587f9f33edefc7]
clinicaltrials:NCT00308412clinicaltrials:NCT00366782Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine [clinicaltrials:NCT00641017]Surveillance Study of Viral Infections Following Lung Transplantation [clinicaltrials:NCT00701922]clinicaltrials:NCT01021397clinicaltrials:NCT01139437clinicaltrials:NCT01249625Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children [clinicaltrials:NCT01254175]clinicaltrials:NCT01302418DAS181 in Patients With Parainfluenza [clinicaltrials:NCT01441024]A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen [clinicaltrials:NCT01644877]An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection [clinicaltrials:NCT01924793]
condition browse [clinicaltrials_vocabulary:condition-browse]
clinicaltrials:NCT00308412clinicaltrials:NCT00366782Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine [clinicaltrials:NCT00641017]Surveillance Study of Viral Infections Following Lung Transplantation [clinicaltrials:NCT00701922]clinicaltrials:NCT01021397clinicaltrials:NCT01139437clinicaltrials:NCT01249625Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children [clinicaltrials:NCT01254175]clinicaltrials:NCT01302418DAS181 in Patients With Parainfluenza [clinicaltrials:NCT01441024]A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen [clinicaltrials:NCT01644877]An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection [clinicaltrials:NCT01924793]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Paramyxoviridae Infections [clinicaltrials_resource:aeef3dc206d9c8dcfa587f9f33edefc7]
Bio2RDF identifier
aeef3dc206d9c8dcfa587f9f33edefc7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:aeef3dc206d9c8dcfa587f9f33edefc7
identifier
clinicaltrials_resource:aeef3dc206d9c8dcfa587f9f33edefc7
title
Paramyxoviridae Infections
@en
type
label
Paramyxoviridae Infections [clinicaltrials_resource:aeef3dc206d9c8dcfa587f9f33edefc7]
@en
Paramyxoviridae Infections